Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $256,620.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 5,200 shares of Twist Bioscience stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the completion of the transaction, the chief executive officer now directly owns 667,318 shares in the company, valued at $32,932,143.30. The trade was a 0.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $52.30 on Friday. The firm has a market capitalization of $3.12 billion, a P/E ratio of -14.53 and a beta of 1.87. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company’s fifty day moving average is $48.84 and its two-hundred day moving average is $46.32.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The business’s revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.75) EPS. On average, sell-side analysts forecast that Twist Bioscience Co. will post -2.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on TWST. Scotiabank lifted their target price on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a report on Tuesday. Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays lowered their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Finally, TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $53.80.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TWST. Thrivent Financial for Lutherans acquired a new position in shares of Twist Bioscience during the 3rd quarter worth $43,992,000. State Street Corp raised its stake in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock worth $31,636,000 after buying an additional 302,884 shares during the last quarter. Finally, ARK Investment Management LLC raised its stake in shares of Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after buying an additional 237,772 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.